Encoded Therapeutics raised $275 million in a Series F round to support its Dravet syndrome drug and expand internal manufacturing. The financing, led by GV with a second undisclosed healthcare investor, also aims to scale genetic medicine capabilities as the company pushes the program toward later-stage development.